Brainstorm cell therapeutics inc. (BCLI)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Cash flows from operating activities:
Net loss

-23,253

-13,948

-

-

-

-

-

-

-

-

Net loss

-

-

-4,952

-4,982

-8,488

-9,246

-4,899

-3,430

-3,918

-2,419

Less - loss for the period from discontinued operations

-

-

-

-

-

-

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

164

110

85

77

87

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

106

97

157

153

162

Severance pay, net

-

-

-

-

-

-

-

-

-23

11

Accrued interest on loans

-

-

-

-

-

-

-

0

3

0

Amortization of discount on short-term loans

-

-

-

-

-

-

-

0

0

0

Change in fair value of options and warrants

-

-

-

-

-

-

-

0

-

-

Shares and options granted to service providers

25

102

62

121

108

198

227

195

-

-

Change in fair value of options and warrants

-

-

-

-

-

-

-

-

0

0

Expenses related to shares and options granted to service providers

-

-

-

-

-

-

-

-

449

96

Deferred Stock-based compensation related to options granted to employees and directors

764

917

554

635

835

1,024

674

560

1,135

-

Change in lease liability

184

-

-

-

-

-

-

-

-

-

Decrease (increase) in other accounts receivable and prepaid expenses

-690

238

2,792

-379

-204

93

-

-

-

-

Stock-based compensation related to options granted to employees

-

-

-

-

-

-

-

-

-

388

Decrease (increase) in accounts receivable and prepaid expenses

-

-

-

-

-

-

155

426

-105

400

Increase (decrease) in trade payables

10,129

3,124

1,079

-824

-373

1,314

-130

114

-63

45

Increase in deferred grant income

-

-2,625

2,625

0

-

-

-

-

-

-

Increase in other accounts payable and accrued expenses

50

170

975

-1,264

212

467

306

-105

-64

48

Revaluation of warrants

-

-

-

-

7

1,743

-174

0

-

-

Erosion of restricted cash

-

-

-

-

-

-

-

0

0

0

Total net cash provided by (used in) operating activities

-

-

-

-

-7,408

-4,487

-

-2,935

-2,223

-2,069

Net cash used in discontinued operating activities

-

-

-

-

-

-

-

0

0

0

Total net cash used in operating activities

-11,247

-12,388

-2,364

-5,858

-

-

-4,054

-2,935

-2,223

-2,069

Cash flows from investing activities:
Purchase of property and equipment

473

369

180

103

45

161

108

90

48

5

Changes in short-term deposit

-6,089

849

-4,170

-6,084

11,237

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

0

0

0

Changes in short-term deposit

-

-

-

-

-

4,290

-2,769

2,750

-

-

Changes in short-term deposit

-

-

-

-

-

-

-

-

0

-

Investment in lease deposit

-

-

4

4

1

-1

5

0

-16

6

Proceeds from issuance of Common stock, net

-

-

-

-

-

9,554

3,576

5,023

3,602

2,118

Net cash used in discontinued investing activities

-

-

-

-

-

-

-

0

0

0

Total net cash provided by (used in) investing activities

5,616

-1,218

3,986

5,977

-

-

2,656

-2,840

-64

1

Cash flows from financing activities:
Total net cash provided by (used in) investing activities

-

-

-

-

-11,283

-4,450

-

-2,840

-64

1

Proceeds from exercise of options

35

25

314

-

-

-

-

-

-

-

Proceeds from issuance of shares in at-the-market (ATM) offering (Note 7)

2,064

0

-

-

-

-

-

-

-

-

Proceeds from issuance of shares and warrants in Registered Direct Offering (Note 7)

3,126

12,040

0

0

2,459

731

-

-

-

-

Proceeds from loans, notes and issuance of warrants, net

-

-

-

-

-

-

-

-

0

0

Credit from bank

-

-

-

-

-

-

-

-

0

-46

Proceeds from equity offering through issuances of equity warrants and common stock through the exercise of previously issued equity warrants

-

-

-

-

12,409

0

8

146

515

88

Redemption of warrants in cash

-

-

-

-

-

600

0

-

-

-

Repayment of short-term loans

-

-

-

-

-

-

-

0

0

0

Total net cash provided by financing activities

-

-

-

-

14,868

9,685

-

5,169

4,117

2,160

Net cash provided by discontinued financing activities

-

-

-

-

-

-

-

0

0

0

Total net cash provided by financing activities

5,225

12,065

314

0

-

-

3,584

5,169

4,117

2,160

Increase in cash and cash equivalents

-406

-1,541

-

-

-

-

-

-

-

-

Increase in cash and cash equivalents

-

-

1,936

119

-3,823

748

2,186

-606

1,830

92

Stock issued for warrants exchange

-

-

-

-

0

1,633

0

-

-

-

Exercise of liability classified warrants

-

-

-

-

130

-42

0

-

-

-

Total non-cash financing activities

-

-

-

-

130

1,675

-

-

-

-

Conversion of convertible loan and convertible note to shares Conversion of trade payable to Common Stock $ 84

-

-

-

-

-

-

-

-

140

324

Conversion of other accounts payable to Common Stock

-

-

-

-

-

-

-

-

-24

487

Conversion of a trade payable to Common Stock

-

-

-

-

-

-

-

-

0

200